Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks ALL, W, BILL, TWLO and CRBU are likely to beat on the bottom line in their upcoming releases.
Zacks Investment Research8/31/2026Positive
CRBU
Caribou Biosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$168.32M
P/E Ratio
—
EPS
$-1.08
Beta
2.28
52W High
$3.54
52W Low
$1.38
50-Day MA
$1.66
200-Day MA
$1.79
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Caribou Biosciences Inc
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies for genetic disorders and oncology. With a robust and diversified pipeline addressing significant unmet medical needs, the company is well-positioned to lead advancements in precision medicine. Caribou's strategic collaborations and unwavering commitment to research excellence underpin its mission to revolutionize treatment paradigms and improve patient outcomes, establishing its foothold as a key player in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $10.04M |
| Gross Profit (TTM) | $-73.82M |
| EBITDA | $-104.61M |
| Operating Margin | -1690.00% |
| Return on Equity | -78.30% |
| Return on Assets | -36.80% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $0.93 |
| Price-to-Book | 1.71 |
| Price-to-Sales (TTM) | 16.77 |
| EV/Revenue | 8.13 |
| EV/EBITDA | -36.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -43.80% |
| Shares Outstanding | $107.21M |
| Float | $102.91M |
| % Insiders | 8.24% |
| % Institutions | 44.85% |
Historical Volatility
HV 10-Day
61.69%
HV 20-Day
53.20%
HV 30-Day
52.49%
HV 60-Day
52.84%
HV Rank
10.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($11.86 target)
1
Strong Buy6
BuyLatest News
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- -- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 -- BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the second quarter of 2026 and provided a business update.
GlobeNewsWire8/13/2026Neutral
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
Zacks Investment Research7/9/2026Negative
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the H.C.
GlobeNewsWire6/29/2026Neutral
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --
GlobeNewsWire6/11/2026Neutral
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case study of a patient who previously received an anti-BCMA CAR-T showed an early complete response that was ongoing as of the data cutoff date --
GlobeNewsWire6/11/2026Neutral
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.
MarketBeat6/9/2026Neutral
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha6/5/2026Neutral
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35pm ET in New York.
GlobeNewsWire5/27/2026Neutral
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha5/16/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRBU and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026